Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIELLE M NICOLAZZO

Allopathic & Osteopathic Physicians Dermatology

NPI
1417362203
CMS profile
1397523
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$4,084.72

163 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,084.72 163

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 4; records 151–163 of 163 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIELLE M NICOLAZZO

NPI 1417362203 · CMS profile ID 1397523

Allopathic & Osteopathic Physicians / Dermatology

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–163 of 163 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417362203?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIELLE M NICOLAZZO, NPI 1417362203, CMS profile ID 1397523. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–163 of 163 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417362203?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DANIELLE M NICOLAZZO, NPI 1417362203, CMS profile ID 1397523. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–163 of 163 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417362203?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DANIELLE M NICOLAZZO, NPI 1417362203, CMS profile ID 1397523, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–163 of 163 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1417362203?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

163 matching records · $4,084.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 163 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–163 of 163.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $23.8001/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795354965 CMS
AbbVie Inc. $28.8601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795354959 CMS
Janssen Biotech, Inc. $26.2801/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788213613 CMS
AbbVie Inc. $22.0601/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795354953 CMS
Janssen Biotech, Inc. $18.5501/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788213609 CMS
Regeneron Healthcare Solutions, Inc. $26.7301/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809609183 CMS
AbbVie Inc. $23.7101/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795354947 CMS
LEO Pharma Inc. $21.9401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842236335 CMS
Journey Medical Corporation $18.8501/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852083557 CMS
PFIZER INC. $18.8901/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832687363 CMS
Lilly USA, LLC $18.4601/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819054735 CMS
DERMIRA, INC. $22.2301/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 764403908 CMS
GENZYME CORPORATION $17.6001/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843677107 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,184.00 111
PY2020 $2,051.81 106
PY2021 $4,084.72 163
PY2022 $1,245.97 45
PY2023 $1,692.18 59
PY2024 $1,749.36 72
PY2025 $1,319.24 66

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Recipient $6,603.52 1
PY2023 Principal investigator $67,946.05 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.80 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.30 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.80 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.30 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.80 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.30 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977201995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977202001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $82.35 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977202007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 12/04/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977202013
Principal investigator 1 Taro Pharmaceuticals USA, Inc. $7,500.00 10/26/2023 Non-covered Recipient Entity
Century Research LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1052646335
Principal investigator 1 Taro Pharmaceuticals USA, Inc. $7,500.00 10/26/2023 Non-covered Recipient Entity
Century Research LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1052646337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.40 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.40 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,564.20 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,564.20 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,449.00 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.40 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,218.60 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,282.50 10/19/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977189835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,701.00 10/02/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977185091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,449.00 10/02/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977185097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,449.00 10/02/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977185103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $207.90 10/02/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977185111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $207.90 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $207.90 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,218.60 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,701.00 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $207.90 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,282.50 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,282.50 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,449.00 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,282.50 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,282.50 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,701.00 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,449.00 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,282.50 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,701.00 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,701.00 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,218.60 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $207.90 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,218.60 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,218.60 07/25/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977170539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,000.00 04/24/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977104749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/24/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977104753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,518.00 04/24/2023 Non-covered Recipient Entity
MPLUSM CONSULTING LLC
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 977104759
Recipient Eli Lilly and Company $6,603.52 03/09/2023 Covered Recipient Physician AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038060139